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Abstract 
The “antibiotic era” saw the discovery of a lot of wonder 
drugs which killed pathogenic bacteria without 
significantly harming the host. Never before had nature 
and sickness seemed so much within the control of 
mankind. The hopes soon died down with the reports of 
antibiotic resistant bacteria. Microbes, such as bacteria, 
viruses, fungi and parasites are living organisms that 
evolve over time. Their primary function is to reproduce, 
thrive, and spread, quickly and efficiently. Therefore, 
microbes adapt to their environment and change in ways 
that ensure their survival. If something stops their ability 
to spread, such as an antimicrobial, genetic changes can 
occur that enable the microbe to survive. This survival 
mechanism is transferred to other bacteria mainly by 
plasmids through vertical and horizontal gene transfer. 
The extensive overuse and misuse of antibiotics by 
human beings has given the problem a larger dimension 
in that now we have superbugs resistant to a variety of 
antibiotics. People need to be informed of the dangers of 
antibiotics and educated on the forms of illnesses that 
antibiotics cannot treat. 
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It is estimated that 90% of the cells in the human body belong to 
non-human organisms, mostly bacteria. Some 100 trillion microbes 
nestle in niches from our teeth to our toes. Without microbes 
human beings would not have been alive. This is just one side of 
the coin. On the other side, there are bacteria which cause life 
threatening diseases to human beings. Man started exercising his 
control over bacteria way back in 1928 when Alexander Fleming 
discovered the first antibiotic, Penicillin. Since then, antibiotics 
have been critical in the fight against infectious diseases caused by 
bacteria. In fact, antimicrobial chemotherapy has been a leading 
cause for the dramatic rise of average life expectancy in the 
twentieth century. However, disease-causing microbes have been 
gaining resistance to these antibiotics with the result that scientists 
had to discover newer and newer antibiotics to kill these resistant 
bacteria. The problem has now grown into a global threat with the 
emergence of super bugs, resistant to more than ten antibiotics. 
2. History of Antibiotics 
The antibiotic era was initiated when Paul Ehrlich first coined the 
term ‘magic bullet’, or chemotherapy, to designate the use of 
antimicrobial compounds to treat microbial infections. In1910 
Ehrlich discovered the first antibiotic drug, Salvarsan, which was 
used against syphilis.[1] The accidental discovery of Penicillin by 
Alexander Fleming in 1928 opened new avenues in the treatment of 
bacterial diseases.[2] 1940s saw the extensive usage of Penicillin 
and by the end of the Second World War, Penicillin became widely 
available and won widespread acceptance. In1935, Gerhard 
Domagk discovered the sulfa drugs[3], thereby paving the way to 
the discovery of the anti-TB drug Isoniazid. Finally, in 1943, the 
first TB drug, Streptomycin, was discovered by Selman 
Waksman[4] who coined the term ‘antibiotics’. Thus antibiotics 
have been used to treat bacterial infections since the 1940s. 
 





3. Basic features of antibiotics 
The definition of an antibiotic as proposed by Waksman is simply a 
description of a use or a laboratory effect or an activity of a 
chemical compound.[5] Today, there are about 4,000 compounds 
with antibiotic properties which are used to treat and prevent 
infections, and to promote growth in animals. Antibiotics are 
derived from three sources: fungi, bacteria and synthetically 
derived. Antibiotics are more effective against actively growing 
bacteria, than against non-growing persisters or spores. When two 
antibiotics are used in combination, the effect could be additive, 
synergistic, or antagonistic. Antibiotics can also be divided into 
broad-spectrum and narrow-spectrum antibiotics. For example, 
Tetracycline, a broad spectrum antibiotic, is active against Gram 
positive bacteria, Gram negative bacteria and even against 
mycobacteria; whereas Penicillin, which has a relatively narrow 
spectrum, can be used mainly against Gram positive bacteria. 
Other antibiotics, such as Pyrazinamide, have an even narrower 
spectrum, and can be used merely against Mycobacterium 
tuberculosis.[6] 
3. Mode of action of Antibiotics 
Bacterial cells grow and divide, replicating repeatedly to reach the 
large numbers present during an infection. To grow and divide, 
organisms must synthesize or take up many types of biomolecules. 
Antimicrobial agents interfere with specific processes that are 
essential for growth and/or division. Based on these processes 
antibiotics can be divided into five major classes - Cell wall 
inhibitors, such as Penicillin and Vancomycin, inhibitors of nucleic 
acid synthesis, such as fluoroquinolones, which inhibits DNA 
synthesis, Rifampin, which inhibits RNA synthesis, protein 
synthesis inhibitors, such as aminoglycosides, anti-metabolites, 
such as the sulfa drugs and cell membrane damaging antibiotics 
such as Polymyxin B and Gramicidin. Elucidation of the structure 
and function of an antibiotic compound is extremely daunting. 
Even though Penicillin was discovered in 1928, the complete 
structure of this relatively simple molecule was not revealed until 






1949, by the X-ray crystallographic studies of Dorothy Crowfoot 
Hodgkin[7] and was confirmed by total synthesis in 1959.[8] 
Studies of modes of action of antibiotics have provided biochemical 
information on ligands and targets throughout antibiotic history.[9, 
10] 
4. History of antibiotic resistance 
Several years before the introduction of Penicillin as a therapeutic, 
a bacterial penicillinase was identified by two members of the 
penicillin discovery team.[11] In his 1945 Nobel Prize lecture, 
Alexander Fleming himself warned of the danger of resistance – “It 
is not difficult to make microbes resistant to Penicillin in the 
laboratory by exposing them to concentrations not sufficient to kill 
them and the same thing has occasionally happened in the 
body….” Indeed, it took little time for Staphylococcus aureus  to 
develop resistance to penicillin. In 1947 just four years after the 
drug started being mass-produced, physicians observed the first 
case of clinical resistance.  
Methicillin was then the antibiotic of choice, but has since been 
replaced by oxacillin due to significant kidney toxicity. MRSA 
(methicillin-resistant Staphylococcus aureus) was first detected in 
Britain in 1961 and is now quite common in hospitals. MRSA was 
responsible for 37% of fatal cases of blood poisoning in the UK in 
1999, up from 4% in 1991. Half of all S. aureus infections in the US 
are resistant to penicillin, methicillin, tetracycline and 
erythromycin. This left vancomycin as the only effective agent 
available at the time. However, strains with intermediate levels of 
resistance (GISA- glycopeptide intermediate Staphylococcus aureus 
or VISA -vancomycin intermediate S. aureus), began appearing the 
late 1990s. The first identified case was in Japan in 1996[12] and 
strains have since been found in hospitals in England, France and 
the US. The first documented strain with complete (>16ug/ml) 
resistance to vancomycin, termed VRSA (Vancomycin-resistant S.  
aureus) appeared in the United States in 2002. VISA-type resistance 
has now been identified in each of the globally spread pandemic 





clones of MRSA..[13] Oxazolidinones, a new class of antibiotics 
became available in the 1990s. The first commercially available 
oxazolidinone, linezolid, is comparable to vancomycin in 
effectiveness against MRSA. Linezolid-resistance in S. aureus was 
reported in 2003.[14] CA-MRSA (Community-acquired MRSA) is 
especially troublesome in hospitals and nursing homes, where 
patients with open wounds, invasive devices, and weakened 
immune systems are at greater risk of infection than the general 
public. 
5. Causes of antibiotic resistance 
 A majority of the antibiotic resistance cases are caused by the 
improper use of antibiotics by humans. These include incorrect 
usage of antibiotics, noncompliance with treatment regimes and 
inappropriate usage of antibiotics in animal feed. Recent studies 
have uncovered the presence of antibiotic resistance genes and 
even resistance-encoding integrons in the gut flora of people who 
live in isolated areas apparently untouched by modern civilization 
and not exposed to antibiotic therapies.[15],[16] 
5.1. Incorrect usage of antibiotics  
When an antibiotic is used inappropriately, for too short a time, at 
too low a dose or at inadequate potency—or for the wrong disease, 
microbes are more likely to develop resistance to that drug. 
According to the U.S. Centre for Disease Control and Prevention 
(CDC), one large part of the problem, is the tendency for people to 
take antibiotics to fight viruses, which they cannot do. Antibiotics 
fight bacteria, not viruses and will not fight colds, flu, bronchitis, 
runny noses, or sore throats not due to Streptococcus. Nonetheless 
says CDC, “more than 10 million courses of antibiotics are 
prescribed each year for viral conditions that do not benefit from 
antibiotics.” 






5.2. Inadequate compliance with treatment regimens 
High levels of antibiotics in the body over a certain period of time 
are necessary to wipe out the entire population of bacteria. But 
since patients often discontinue treatment after just a few pills 
when they start to feel better, with only a partial dose of the 
medicine, only the weakest bacterial populations in the body are 
destroyed. Meanwhile, the surviving bacteria may develop 
resistance to the antibiotic, and will continue to multiply, thereby 
passing on the trait to future generations and even to other 
microorganisms in the body. Resistant bacteria can then be passed 
to other human hosts. 
5.3. Antibiotic use in animal feed 
Many developed countries use antibiotics for veterinary 
purposes—to accelerate weight gain and to prevent and treat 
diseases in animals.  Farmers and ranchers use antibiotics heavily 
in beef, pig and poultry industry.  In fact, the Union of Concerned 
scientists (UCS), a non-profit research and advocacy group, 
estimates that 70 percent of all antibiotics are used as additives in 
the feed given to healthy pigs, poultry and cattle. These drugs leave 
the animals’ bodies as waste and work their way into local water 
supplies, as well as right into the food chain. Use of antibiotics in 
farm animals promotes the development of drug-resistant microbes 
in those animals. Drug resistance in animals may lead to drug 
resistance in humans, because the drug-resistant bacteria can be 
transmitted from animals to humans. Apart from the resistance 
problem, this can also cause physiological damage to local resident 
populations of insects, birds, animals, and humans.[17] 
6. Mechanisms of resistance 
Some of the important mechanisms by which a microorganism can 
resist an antimicrobial agent are (1) to alter the receptor for the 
drug (the molecule on which it exerts its effect); (2) to decrease the 
amount of drug that reaches the receptor by altering entry or 





increasing removal of the drug and (3) to destroy or inactivate the 
drug. Bacteria can possess one or all of these mechanisms 
simultaneously. A brief summary of the important resistance 
mechanisms of a few antibiotics are listed in table 1. 
 
 
Table 1. Mechanisms of Antibiotic Resistance in Bacteria 
6.1. Resistance due to altered receptors 
The β-lactam ring is part of the core structure of several families of 
antibiotics, the principal ones being the penicillins, cephalosporins, 
carbapenems and monobactams which are, therefore called β-
lactam antibiotics. Nearly all of these antibiotics work by inhibiting 
bacterial cellwall biosynthesis. Some bacteria are capable of making 
changes in receptors for β-lactams. In 1977, Streptococcus pneumoniae 
strains resistant to Penicillin G were encountered in South 
Africa.[18]  Plasmids were not the cause of the resistance.  
Penicillin-resistant S pneumoniae cells have altered penicillin-
binding proteins, which bind penicillin less well. Resistance of S 
pneumoniae to penicillin has been increasing and there are now 
relatively resistant isolates in many parts of the world. Altered 
penicillin-binding proteins also account for the resistance of some 
Staphylococcus aureus strains to β-lactamase-stable penicillins 
(methicillin-resistant strains). Staphylococcal organisms resistant to 
Antibiotic Method of resistance 
Chloramphenicol reduced uptake into cell 
Tetracycline active efflux from the cell 
β-lactams, Erythromycin, 
Lincomycin 
eliminates or reduces binding of antibiotic 
to cell target 
β-lactams, Aminoglycosides enzymatic cleavage to inactivate antibiotic 
molecule 
Sulfonamides, Trimethoprim metabolic bypass of inhibited reaction 
Trimethoprim, 
sulphoninamides 
overproduction of antibiotic target 
(titration) 






methicillin are resistant to all penicillins, cephalosporins, and 
carbapenems. Enterococci are resistant to all cephalosporins 
because of failure to bind to the penicillin-binding proteins. The β-
lactams induce synthesis of a new penicillin-binding protein, 
PBP2a, which does not bind any β-lactam.  
Vancomycin is a glycopeptide antibiotic which acts by inhibiting 
cell wall synthesis in Gram-positive bacteria. Due to the different 
mechanism by which Gram-negative bacteria produce their cell 
walls and the various factors related to entering the outer 
membrane of  Gram  negative organisms, Vancomycin is not active 
against Gram-negative bacteria (except some non-gonococcal 
species of Neisseria). It has traditionally been reserved as a  last 
resort drug, used only after treatment with other antibiotics had 
failed Some transposon encoded enzymes alter the side chains in 
the cell wall peptidoglycan thereby preventing the binding of 
vancomycin which results in resistant enterobacteria.  
Rifampicin is a semisynthetic compound derived from 
Amycolatopsis rifamycinica. It inhibits DNA-dependent RNA 
Polymerase in bacterial cells by binding its beta-subunit, thus 
preventing transcription to RNA and subsequent translation to 
proteins. Rifampicin is used against a number of bacteria, but it is 
best known for activity against Mycobacteria responsible for 
causing tuberculosis and leprosy. Rifampicin can be used as 
monotherapy for a few days as prophylaxis against meningitis, but 
resistance develops quickly during long treatment of active 
infections, so the drug is always used against active infections in 
combination with other antibiotics. The resistance of bacteria to 
rifampin is caused by an alternation of one amino acid in DNA-
directed RNA polymerase, which results in reduced binding of 
rifampin. The degree of resistance is related to the degree to which 
the enzyme is changed. This form of resistance occurs at a low level 
in any population of bacteria so that resistance develops by natural 
selection during a course of therapy.[19]  
Quinolones are a family of synthetic broadspectrum antibiotics. 
The first generation of the quinolones began with the introduction 





of nalidixic acid in 1962 for treatment of urinary tract infections in 
humans. These drugs interfere with DNA replication by inhibiting 
bacterial DNA gyrase or the topoisomerase II enzyme, thereby 
inhibiting DNA replication and transcription. Quinolones can enter 
cells easily via porins and therefore, are often used to treat 
intracellular pathogens such as Legionella pneumophila and 
Mycoplasma pneumoniae. For many Gram-negative bacteria, DNA 
gyrase is the target, whereas topoisomerase IV is the target for 
many Gram-positive bacteria. Resistance to quinolones can be 
caused by mutations in DNA gyrase subunits A or B, reduced outer 
membrane permeability in gram-negative cells, or to active efflux 
transporters found in many bacteria. The highest level of resistance 
to the newer fluoroquinolones is most frequently associated with 
chromosomal mutations, causing amino acid substitutions in a 
highly conserved region in the A subunit of DNA gyrase. Multiple-
mechanisms of resistance can occur in a single isolate of bacteria, 
leading to a higher level of resistance to many fluoroquinolones. 
.[20] 
6.2. Resistance Due to Decreased Entry of a Drug 
Tetracycline is a broad-spectrum polyketide antibiotic which binds 
to the 30S subunit of microbial ribosomes. It inhibits protein 
synthesis by blocking the attachment of charged aminoacyl-tRNA. 
Thus it prevents the introduction of new amino acids to the nascent 
peptide chain. The action is usually inhibitory and reversible upon 
withdrawal of the drug. Resistance to tetracyclines results from 
changes in permeability of the microbial cell envelope. In 
susceptible cells, the drug is concentrated from the environment 
and does not readily leave the cell. In resistant cells, the drug is not 
actively transported into the cell or leaves it so rapidly that 
inhibitory concentrations are not maintained. This is often plasmid-
controlled. It is a protein synthesis inhibitor. Tetracycline resistance 
is common in both Gram-positive and Gram-negative bacteria. In 
most cases it is plasmid encoded and inducible; however, 
chromosomal, constitutive resistance is found in some organisms 
such as Proteus species.  






Tetracycline resistance is a major concern because it is located on 
plasmids near insertion sites and these plasmids readily acquire 
other genetic information to enlarge the spectrum of resistance. The 
widespread use of tetracycline in animal feeds may be a factor in 
the extensive, worldwide resistance of members of the 
Enterobacteriaceae, particularly enteric species such as Salmonella, 
to tetracyclines and subsequently to many other drugs.[21] Not 
only can tetracycline resistance move among members of the 
Enterobacteriaceae on plasmids, but plasmids mediating 
tetracycline resistance have moved between S aureus, S epidermidis, 
S pyogenes, S pneumoniae, and S faecalis. 
6.3. Due to Destruction or Inactivation of a Drug 
Chloramphenicol is a broadspectrum antibiotic effective against a 
wide variety of Gram-positive and Gram-negative bacteria, 
including most anaerobic organisms. The most serious adverse 
effect associated with chloramphenicol treatment is bone marrow 
toxicity, which may occur in two distinct forms: bone marrow 
suppression - a direct toxic effect of the drug and is usually 
reversible  - and aplastic anemia.[22] Many Gram-positive and 
Gram-negative bacteria, including some recently discovered H 
influenzae strains, are resistant to chloramphenicol because they 
possess the enzyme chloramphenicol transacetylate, which 
acetylates hydroxyl groups on the chloramphenicol structure. This 
enzyme, unlike the aminoglycoside-inactivating enzymes and β-
lactamases, is an intracellular enzyme of higher molecular weight 
and subunit structure. Acetylated chloramphenicol binds less well 
to the 50S ribosome.[23] 
7. Superbugs 
The increasing emergence of superbugs is a direct consequence of 
antibiotic misuse. Resistance of microbes to drugs can be classified 
into MDR, XDR and PDR. MDR or multiple drug resistant bacteria 
are those which are resistant to antibiotics of at least three different 
classes. XDR or extensively drug resistant bacteria are those which 





are resistant to all antibiotics except only one class of antimicrobial 
agent used to treat the infections caused by this.PDR or pan-drug 
resistant bacteria are those which are resistant to antibiotics of all 
classes of antimicrobial agents used to treat the infections.  
The term “superbugs” refers to microbes with enhanced morbidity 
and mortality due to multiple mutations endowing high levels of 
resistance to the antibiotic classes specifically recommended for 
their treatment; the therapeutic options for these microbes are 
reduced, and periods of hospital care are extended and more costly. 
In some cases, super resistant strains have also acquired increased 
virulence and enhanced transmissibility. Superbugs can be 
dangerous because of the limited number of treatment options 
available. Among some of the deadly superbugs are methicillin-
resistant Staphylococcus aureus (MRSA), Klebsiella pneumonia, 
Clostridum difficile Acinetobacter baunammii, Pseudomonas aeruginosa 
and Vancomycin-resistant Enterococcus faceium.[24],[25],[26] 
The development of MDR Staphylococcus aureus well illustrates the 
battle between the agile pathogens and drugs. S. aureus is a 
bacterium that harmlessly lives in the human body but can cause 
various kinds of infections. After the clinical application of 
Penicillin in the 1940s, S. aureus soon adapted to the treatment 
mechanism of penicillin, and by the 1950s, almost half of S. aureus 
strains had become resistant to Penicillin. A new antibiotic, 
Methicillin, developed in the 1960s kills S. aureus by interfering 
with the bacterium’s ability to form a cell wall. Methicillin was a 
huge success in the initial years of its discovery, but within a few 
years, some strains of S. aureus germ picked up a gene called mecA 
which  reduced the ability of Methicillin  to interfere with the S. 
aureus cell wall by a thousand fold.  
 
Tuberculosis is the world’s number one killer among infectious 
diseases. Combined with HIV, MDR TB has become a real menace 
especially in African countries. MDR-TB is caused by strains of 
Mycobacterium tuberculosis that are resistant to at least the 
antibiotics isoniazid and rifampicin.  A subset of MDR-TB, 
extensively drug-resistant tuberculosis (XDR-TB),  caused by rare 






strains that are resistant to isoniazid and rifampicin, as well as 
second-line (or follow-up) medications have spread rapidly in the 
last decade or so.[27],[28] And now there are TDR strains, which 
are totally drug resistant.[29] 
8. NDM-1 
NDM-1 stands for New Delhi metallo-beta-lactamase, which is an 
enzyme produced by certain strains of bacteria that have recently 
acquired the genetic ability to make this compound. The enzyme is 
active against compounds that contain the beta-lactam ring. 
Unfortunately, many antibiotics contain this ring, including the 
penicillins, cephalosporins and the carbapenems. Bacteria that 
produce NDM-1 are resistant to all commonly used beta-lactam 
antibiotics. Some antibiotics like aminoglycosides and 
fluoroquinolones do not contain beta-lactam rings. Unfortunately, 
the bacteria that have acquired NDM-1 have also acquired other 
resistance factors and most are already resistant to aminoglycosides 
and fluoroquinolones. NDM production has enabled these bacteria 
to transform into true superbugs which are resistant to virtually all 
commonly used antibiotics. Cases of NDM-1 infection are usually 
caused by Gram negative bacteria from the Enterobacteriaceace 
family (Klebsiella and Escherichia coli.). The plasmid-mediated 
blaNDM-1 gene encodes a metallo-β-lactamase (MBL) with high 
carbapenemase activity and was first identified in Escherichia coli 
and Klebsiella pneumoniae in Sweden from a patient transferred from 
India.[30] It was later identified in different enterobacterial species 
from a series of patients in the United Kingdom, India, and 
Pakistan[31] and also from Australian and U.S. patients.[32] 
9. Future of Antibiotics 
If mankind has to win over microbes in the race, extremely 
strategic and diversified measures have to be adopted in tackling 
the bugs. These include discovery of novel antimicrobial 
compounds and new targets for antimicrobials. The antibiotic 
treatment choices for already existing or emerging hard-to-treat 





multidrug-resistant bacterial infections are limited, resulting in 
high morbidity and mortality rates. Majority of antimicrobials in 
use today have been isolated in the golden era of antibiotic 
discovery from a limited number of ecological niches and 
taxonomic groups, mainly from soil Actinomyces. Some possible 
approaches to tap the novel antimicrobial diversity is the 
exploration of ecological niches other than soil, such as the marine 
environment[33],[34], borrowing antimicrobial peptides and 
compounds from animals and plants[35], mimicking the natural 
lipopeptides of bacteria and fungi[36], accessing the uncultivated 
portion of microbiota through the metagenomic approach[37] and 
finally finding drugs possessing dual target activities, such as a 
rifamycin–quinolone hybrid antibiotic, CBR-2092.[38] 
Almost all the antibiotics discovered in the past decades target the 
same cellular processes like translation, cell wall biosynthesis, 
DNA/RNA metabolism etc. Since we have a sufficient amount of 
genome sequence data available presently, it’s possible to have 
more precise drug targets. The comparison of metabolic pathways 
in commensal and pathogenic bacteria may help to identify the 
novel drug/target combinations in pathogens.[39] Successful 
implementations of this approach have already been demonstrated 
in the suppression of an important virulence factor, type III 
secretion system[40] and in the inhibition of the QseC-mediated 
activation of virulence gene expression in several pathogens.[41] 
The drugs initially designed for a different purpose may find 
application as antimicrobials. For example, BPH-652, a 
phosphonosulfonate, which was previously tested for cholesterol-
lowering activity in humans as targeting the enzyme in cholesterol 
biosynthesis pathway, squalene synthase also inhibits an important 
enzyme involved in Staphylococcus aureus virulence, 
dehydrosqualene synthase and thus may be considered as a 
candidate drug to control MRSA.[42] Combination therapy like 
coupling antibiotics with an antibiotic-enhancing phage, has 
demonstrated the potential to be a promising antimicrobial 
intervention.[43] 







The war between bugs and man had begun centuries back. Every 
time humans emerge with a drug to combat microbes, within a few 
years bugs outsmart the humans and become resistant to it. This 
chase has been going on for decades. If man doesn’t keep pace with 
the bugs by emerging with newer and stronger drugs, we are sure 
to lose the battle with the bugs. The need of the hour is to prevent 
antibiotic resistance by adhering to strict norms during its 
prescription and usage and also to devise novel strategies for 
equipping ourselves with newer and more efficient drugs to launch 
the defense during future outbreaks of drug resistant microbes. 
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